This is not a material change, it's business as usual.
In the ongoing American struggle over prescription drug costs, President Trump's second term has brought a flurry of pharmaceutical initiatives — negotiations, discount portals, and public pressure campaigns — that have generated considerable noise but modest relief for most patients. The deeper, quieter story is that the most meaningful savings are flowing from a Biden-era Medicare negotiation program, now continued, that has secured historic discounts on dozens of high-cost drugs. For the roughly six in ten Americans who worry about affording their medications, the gap between political promise and lived reality remains wide, and the burden of navigating that gap falls largely on patients themselves.
- Nearly a thousand brand-name drugs raised their prices in January 2026 alone, making 2025 the record year for list price hikes — even as the White House staged public negotiations with pharmaceutical executives.
- TrumpRx, the administration's discount portal, offers striking headline numbers but applies mainly to uninsured cash-payers, features older drugs, and in some cases lists medications at prices still far above available generic alternatives.
- Harvard and independent drug-pricing experts have called the Trump deals opaque, unenforceable, and designed more for publicity than structural change — and the White House has declined to explain how the program actually works.
- The genuine, measurable savings are arriving through the continued Medicare drug negotiation program inherited from the Biden administration, delivering over $20 billion in annual savings and capping out-of-pocket costs for Medicare enrollees.
- For the millions of uninsured or privately insured Americans outside Medicare, meaningful relief remains elusive — requiring patients to become skilled comparison shoppers for medicines they cannot afford to go without.
President Trump entered his second term with pharmaceutical pricing squarely in his crosshairs. He sent letters to manufacturers demanding voluntary cuts, held one-on-one negotiations with industry executives at the White House, launched a discount portal called TrumpRx, and promised to accelerate generic versions of costly specialty drugs. The urgency behind these moves reflects a genuine public crisis: roughly six in ten American adults worry about affording their medications, and Americans pay approximately three times what patients in other wealthy countries pay for the same drugs.
The results, however, have not matched the rhetoric. January 2026 saw nearly a thousand brand-name drugs increase in price, and 2025 set a record for list price hikes. When Pfizer raised prices on 71 drugs in the first week of 2026 — cutting just one — it became clear that public negotiations were not halting the underlying machinery of pharmaceutical pricing. Antonio Ciaccia of drug-tracking firm 46brooklyn called it 'business as usual.'
TrumpRx, launched in February, offers discounts that sound dramatic — Wegovy for $199 a month for uninsured patients, fertility drugs at a fraction of their list price. But the portal consists largely of Pfizer's offerings, applies only to cash-paying patients without insurance, and frequently lists drugs at prices still well above available generics. Humira appears at $950 a dose, down from nearly $7,000 — but biosimilar versions already sell for as little as $207.60. Harvard's Aaron Kesselheim described the Trump announcements as 'one-off agreements made for publicity purposes' that leave the underlying pricing system untouched.
The most substantive savings are arriving from a quieter source: the continuation of the Biden-era Medicare drug negotiation program. Ten high-cost drugs took effect with negotiated discounts exceeding fifty percent on January 1st, and forty drugs in total are expected to save Medicare more than $20 billion annually while capping out-of-pocket costs for enrollees at $2,000 per year. 'This is historic,' Kesselheim noted — the first time the United States has negotiated drug prices the way every other developed country does.
Yet those savings reach only Medicare beneficiaries. For the broader population of Americans struggling with drug costs, the landscape is largely unchanged. Fertility drug discounts on TrumpRx reduce the cost of an IVF cycle by roughly ten percent — but a cycle still runs $15,000 to $25,000, and most women need multiple rounds. Patent protections will keep generic Wegovy off U.S. shelves until 2039, even as cheaper versions arrive in Canada this year. The central question for patients is whether they have the time, knowledge, and resources to navigate a system that increasingly asks them to shop for their own survival.
President Trump arrived at his second term with a pharmaceutical industry in his sights. Since taking office, he has announced a series of initiatives meant to wrestle down drug prices—letters to manufacturers demanding voluntary cuts, one-on-one negotiations with pharmaceutical executives at the White House, the launch of a discount portal called TrumpRx, promises to fast-track generic versions of expensive specialty drugs. The urgency behind these moves is real. Polling shows that roughly six in ten American adults worry about affording their medications, and more than eight in ten believe prescription drug prices are unreasonable. Americans pay roughly three times what patients in other developed countries pay for identical drugs.
Yet the results so far tell a more complicated story. In January 2026 alone, nearly a thousand brand-name drugs went up in price. The year 2025 saw the highest number of list price increases on record. When Pfizer raised prices on 71 drugs in the first week of 2026—averaging a five percent increase and cutting just one drug's price—it became clear that the administration's public negotiations were not stopping the underlying machinery of pharmaceutical pricing. "This is not a material change, it's business as usual," said Antonio Ciaccia, co-founder of 46brooklyn, a firm that tracks drug prices.
The TrumpRx portal, launched in February, offers discounts that sound dramatic on paper. Fertility drugs from EMD Serono, for instance, can cost as little as $168 per cycle instead of $966. Novo Nordisk's Wegovy, a GLP-1 weight loss drug, dropped to $199 a month for uninsured patients. But these deals come with sharp limits. The site consists largely of Pfizer's drugs—about 30 of the company's roughly 85 offerings—and the discounts apply mainly to people without insurance who pay cash out of pocket. For those with coverage, other discount programs often offer far more options. A patent law expert at the University of Alabama noted that many of the drugs on TrumpRx are old medications or ones competing with much cheaper generic alternatives already on the market. Colestid, a cholesterol drug, appears on TrumpRx at fifty percent off—$127.91—while generic versions sell for about $17 elsewhere. Humira, Amgen's arthritis drug, was added at $950 a dose, down from nearly $7,000, but biosimilar versions are already available for as little as $207.60.
Harvard Medical School professor Aaron Kesselheim, whose research focuses on drug pricing, called the Trump announcements "one-off agreements made for publicity purposes" that "don't change anything about the way drugs are priced." He added that the agreements are opaque and unenforceable. The White House did not answer questions about how TrumpRx works or which drugs are covered.
The genuine savings, it turns out, are coming from a quieter source: the continuation of a Biden-era program that allows Medicare to negotiate prices directly with manufacturers. Ten expensive drugs—blood thinners, insulins, medicines for inflammatory conditions—saw negotiated discounts of well over fifty percent, taking effect January 1st. An additional fifteen high-priced drugs, including popular weight loss and cancer medications, were subject to negotiation in 2025, with discounted prices arriving next year. Fifteen more are set for negotiation this year. All told, the forty negotiated drugs are expected to save Medicare more than twenty billion dollars annually and cap out-of-pocket spending for Medicare patients at two thousand dollars per year for prescription drugs. "This is historic because it's the first time the United States has negotiated prices, like every other developed country," Kesselheim said. "And guess what? Innovation didn't stop."
But these savings reach only Medicare beneficiaries. The newer Trump initiatives help some other patients—particularly those without insurance willing to hunt for discounts—but the relief is patchy and requires knowledge of where to look. For the millions of Americans struggling to afford their medications, the landscape remains largely unchanged. The fertility drug discounts on TrumpRx might reduce the cost of a single IVF cycle by about ten percent, according to the American Society for Reproductive Medicine, but a cycle still costs fifteen thousand to twenty-five thousand dollars, and most women need two or three cycles. Meanwhile, patent protections will keep generic versions of Wegovy off the U.S. market until 2039, even as cheaper generics are expected to arrive in Canada this year at as low as seventy-three dollars a month. The question facing patients now is whether they have the time, knowledge, and resources to become comparison shoppers for their own essential medicines.
Citações Notáveis
This is not a material change, it's business as usual.— Antonio Ciaccia, co-founder of 46brooklyn drug pricing firm
One-off agreements made for publicity purposes. They don't change anything about the way drugs are priced.— Aaron Kesselheim, Harvard Medical School professor of medicine
This is historic because it's the first time the United States has negotiated prices, like every other developed country. And guess what? Innovation didn't stop.— Aaron Kesselheim, on Medicare drug price negotiation
A Conversa do Hearth Outra perspectiva sobre a história
So Trump made all these announcements about drug prices. Did any of it actually work?
Some of it did, but not in the way the headlines suggested. The real savings are coming from Medicare negotiating prices directly with manufacturers—that's saving over twenty billion dollars a year. But that only helps people on Medicare.
What about TrumpRx, the website he launched?
It's mostly older drugs or ones that already have much cheaper generic versions available. If you're uninsured and paying cash, you might find a deal on fertility drugs or weight loss medications. But if you have insurance, you probably have better options already.
Why would drug companies agree to lower prices on drugs that are already losing money to generics?
Exactly. They're not really sacrificing anything. Those are sales they wouldn't have made anyway. In exchange, some companies got tariffs lifted or faster FDA approval for other drugs. It looks good in a press release, but the underlying pricing system hasn't changed.
And what about the one-on-one negotiations Trump did with pharma executives?
Those were largely theater. Pfizer raised prices on 71 drugs in the first week of 2026, averaging five percent increases. The agreements are vague, unenforceable, and don't address how drugs are actually priced.
So who actually benefits from all this?
Medicare patients benefit from the negotiation program. Some uninsured people might find deals on specific drugs. But the average American struggling to afford their medications? They're largely untouched. The system itself hasn't changed.